Table 1 Associations between tamoxifen and endoxifen and 4OH-tamoxifen concentrations and biomarker levels at 1 year.

From: Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

 

Tamoxifen

Endoxifen

Z-4OHtam

IGF-1

 All women

n = 154

n = 153

n = 153

−0.110a (0.038)

−0.096a (0.067)

−0.088a (0.091)

 Pre-menopause

n = 56

n = 56

n = 56

−0.086 (0.422)

−0.003 (0.979)

0.042 (0.687)

 Peri/post-menopause

n = 98

n = 97

n = 97

−0.179 (0.005)

−0.198 (0.002)

−8.873 (0.001)

SHBG

 All women

n = 154

n = 153

N = 153

0.100a (0.101)

0.045 (0.460)

0.100 (0.183)

 Pre-menopause

n = 56

 

—

−0.048 (0.627)

—

 

 Peri/post-menopause

n = 98

 

—

0.172 (0.009)

—

 

CRPb

 All women

n = 154

n = 153

N = 153

−0.182 (0.007)

−0.136 (0.038)

−0.255 (0.014)

 Pre-menopause

—

—

—

 Peri/post-menopause

—

—

—

  1. Data are beta standardized coefficients (p-values in parentheses) of biomarker parameters from linear regression models with biomarker level as response variable, metabolite level as explanatory, adjusting for age, medication possession rate at 1 year, BMI, menopausal status, and biomarker level at baseline.
  2. ap interactions between biomarker level and menopausal status at baseline: ≤0.2; p-interaction for tamoxifen, endoxifen and 4OH-tamoxifen with menopause on IGF-I = 0.04, 0.20 and 0.14, respectively; p-interaction for tamoxifen with menopause on SHBG = 0.04
  3. bCRP was log-transformed in linear regression models.
  4. Note: Coefficients were calculated also in subgroups by menopausal status when p for interaction ≤0.2.
Back to article page